These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21945487)

  • 1. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.
    Karalis V; Macheras P; Symillides M
    Eur J Pharm Sci; 2005 Sep; 26(1):54-61. PubMed ID: 15955680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA.
    Karalis V; Symillides M; Macheras P
    Pharm Res; 2012 Apr; 29(4):1066-77. PubMed ID: 22203326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel scaled bioequivalence limits with leveling-off properties.
    Kytariolos J; Karalis V; Macheras P; Symillides M
    Pharm Res; 2006 Nov; 23(11):2657-64. PubMed ID: 17048119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel scaled average bioequivalence limits based on GMR and variability considerations.
    Karalis V; Symillides M; Macheras P
    Pharm Res; 2004 Oct; 21(10):1933-42. PubMed ID: 15553242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).
    Tothfalusi L; Endrenyi L; Midha KK
    Int J Clin Pharmacol Ther; 2003 May; 41(5):217-25. PubMed ID: 12776813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample sizes for designing bioequivalence studies for highly variable drugs.
    Tothfalusi L; Endrenyi L
    J Pharm Pharm Sci; 2012; 15(1):73-84. PubMed ID: 22365089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
    Endrenyi L; Tothfalusi L
    J Pharm Pharm Sci; 2009; 12(1):138-49. PubMed ID: 19470298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
    Paixão P; Gouveia LF; Morais JA
    Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical considerations into the new EMA guideline on bioequivalence.
    Marzo A; Fontana E
    Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new European Medicines Agency guideline on the investigation of bioequivalence.
    Morais JA; Lobato Mdo R
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An area correction method to reduce intrasubject variability in bioequivalence studies.
    Abdallah HY
    J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.